Granted Patent B2

US 10,711,314 · App. 15/963,784 · Granted Jul 14, 2020

Inventors: Leonard Luan C. Dang (Boston, MA); Stefan Gross (Brookline, MA); Hyun Gyung Jang (Waltham, MA); Shengfang Jin (Newton, MA); Shin-San Michael Su (Boston, MA); Craig Thompson (New York, NY)

Assignee: Agios Pharmaceuticals, Inc.

C12Q1/6886A61K31/015A61K31/05A61K31/122A61K31/194A61K31/225A61K31/355A61K31/375A61K31/381A61K31/522A61K31/7004A61K31/713A61K38/063A61K38/44C12Q1/32C12Q2600/106C12Q2600/112C12Q2600/118C12Q2600/136C12Q2600/156

Abstract

Claims (14)

1. A method of diagnosing a subject having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with:

(a) the presence, distribution, or level of an IDH1 mutant enzyme that has 2-hydroxyglutarate (2HG) neoactivity and has other than an Arg at residue 100; or

(b) elevated levels of 2HG due to the presence of an IDH1 mutant enzyme that has 2HG neoactivity and has other than an Arg at residue 100,

wherein said method comprises analyzing the presence, distribution, or level of 2HG in the subject or a tissue, bodily product, or bodily fluid of said subject by mass spectroscopy analysis and wherein if the subject or the tissue, bodily product, or bodily fluid shows an increase in the presence, distribution or level of 2HG compared to a non-diseased subject, tissue, bodily product or bodily fluid of the same type, then the subject is diagnosed as having the cell proliferation related disorder.

2. The method of claim 1 wherein said cell proliferation-related disorder is selected from the group consisting of glioma, prostate cancer, acute lymphoblastic leukemia, myelodysplasia, and myelodysplastic syndrome.

3. The method of claim 1 , wherein said bodily fluid is blood or plasma.

4. The method of claim 1 , wherein the mass spectroscopy is LC-MS or GC-MS.

5. A method of evaluating a subject for the susceptibility to a cell proliferation-related disorder associated with:

(a) the presence, distribution, or level of an IDH1 mutant enzyme that has 2HG neoactivity and has other than an Arg at residue 100; or

(b) elevated levels of 2HG due to the presence of an IDH1 mutant enzyme that has 2HG neoactivity and has other than an Arg at residue 100,

wherein said method comprises analyzing the presence, distribution, or level of 2HG in the subject or a tissue, bodily product, or bodily fluid of said subject by mass spectroscopy analysis and wherein if the subject or the tissue, bodily product, or bodily fluid shows an increase in the presence, distribution or level of 2HG compared to a non-diseased subject, tissue, bodily product or bodily fluid of the same type, then the subject is diagnosed as being susceptible to the cell proliferation related disorder.

6. The method of claim 5 wherein said cell proliferation-related disorder is selected from the group consisting of glioma, prostate cancer, acute lymphoblastic leukemia, myelodysplasia, and myelodysplastic syndrome.

7. The method of claim 5 , wherein said bodily fluid is blood or plasma.

8. The method of claim 5 , wherein the mass spectroscopy is LC-MS or GC-MS.

Assignments (6)

Continuity (8)